Kazem Rahimi, ESC 2020 – Blood Pressure Lowering for Prevention of Cardiovascular Events
We spoke to Dr Kazem Rahimi (Oxford University, Oxford, UK) about the Blood Pressure Lowering Treatment Trialists Collaboration (BPLTTC) and their recent study examining blood pressure lowering to prevent cardiovascular events.
- Could you tell us a little about the Blood Pressure Lowering Treatment Trialists Collaboration (BPLTTC) and its objectives? (0.13)
- Could you give us an overview of the aims and design of the Blood Pressure Lowering for Prevention of Cardiovascular Events across Different Levels of Blood Pressure study? (0.53)
- What were the findings of this study? (1.44)
- What factors should be considered when prescribing blood pressure-lowering medication? (2.32)
- What future studies are planned? (3.48)
Speaker disclosures: Dr Kazem Rahimi has received funding from British Heart Foundation, NIHR Biomedical Research Centre and Oxford Martin School, University of Oxford.
Support: Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Dr Kazem Rahimi, September 2020.
Share this Video
Related Videos In Cardiovascular Disease
Annapoorna Kini, ACC 2023: Evolocumab in patients with stable coronary artery disease, the Yellow III study
The Yellow III study aimed to assess the effect of evolocumab in combination with statins on plaque morphology in patients with stable coronary artery disease. In this touchCARDIO interview, we speak with Dr Annapoorna Kini (Cardiac Catheterization Laboratory, Mount Sinai Medical Centre, New York, NY, USA) to discuss the Yellow series, with focus on the […]
Annapoorna Kini, ACC 2023: PCSK9 inhibitors for acute coronary syndrome
Evolocumab is a proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9 inhibitor). When used in combination with statins, reduced plaque volume has been observed in patients with acute coronary syndrome (ACS). In this touchCARDIO interview, we speak with Dr Annapoorna Kini (Cardiac Catheterization Laboratory, Mount Sinai Medical Centre, New York, NY, USA) to discuss the use […]
Divaka Perera, ACC 2023: Myocardial viability in patients with ischaemic left ventricular dysfunction, the REVIVED-BCIS2 trial
The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the REVIVED-BCIS2 trial, its findings and the impact these results will likely […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!